Combination therapy for hypertension 2013: An update

Salahuddin, Ayesha; Mushtaq, Muzammil; Materson, Barry J.

doi:10.1016/j.jash.2013.04.013

Cited by 18 publications

(14 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, side effects caused by one drug class may be negated by the actions of another drug class that elicits opposing physiological compensatory mechanisms, resulting in a more favorable tolerability profile. [16][17][18][19] Among the five main classes of antihypertensive drugs, the combination of either an angiotensin converting enzyme inhibitor (ACEi) or an ARB, which both inhibit the renin-angiotensin system, a calcium channel blocker is the most commonly used double-drug regimen. 20 Compared with separate tablets for each drug, fixed-dose combination (FDC) tablets are associ-ated with a higher rate of adherence to treatment, and, as a consequence, a greater proportion of patients attaining their BP goal over time.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness, Safety and Tolerability of Combination of Amlodipine and Valsartan in Hypertensive Patients

et al. 2016

View full text Add to dashboard Cite

Background: Hypertension is a major public health challenge worldwide and majority of patients fail to achieve blood pressure control with monotherapy. The purpose of the present study was to assess effectiveness of single pill combination of amlodipine and valsartan as anti-hypertensive therapy under real life conditions.Methods: This prospective, non-interventional, open-label, non-comparative observational, multicenter study was conducted from July 2013 to October 2014. This study was carried out among the hypertensive patients who were treated with single pill of amlodinpine and valsartan. Data were collected at baseline and end of study time points.The study was considered as completed for an individual patient when the treatment was completed approximately 26 ± 8 weeks.The assignment of the patient to the therapy was decided within the current practice and the medical indication, and was clearly separated from the decision to include the patient in the study.Results: The study enrolled 278 patients. Of these 236(84.9%) patients completed the study. Nonserious adverse events were reported in 19(6.8%) cases. During enrollment of the study majority patients were in the more than 140 mmHg systolic BP group which was 205(73.7%) patients which was gradually decreased to 101(36.3%) and 59(21.2%) at 2nd and final visit respectively (p=<0.05). The proportion of patients in the group of more than 90 mmHg diastolic BP was gradually decreasing from baseline to the final visit during the single pill combination of amlodinpine/valsartan which was 95(34.2%) during enrollment followed by 42(15.1%) and 33(11.9%) patients in 2nd visit and final visit respectively. Considering the diabetes mellitus (DM) patients the high SBP was gradually decreased from 74(77.9%) to 50(52.6%) patients during enrollment and final visit respectively. Again in DM patients the high DBP (>80 mmHg) was gradually decreased from 61(64.2%) patients to 29(30.5%) patients during enrollment and final visit respectively.Conclusion: The single pill combination of amlodipine/valsartan is significantly reduced the blood pressure among the hypertensive patients in real world settings.Cardiovasc. j. 2016; 9(1): 13-18

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness, Safety and Tolerability of Combination of Amlodipine and Valsartan in Hypertensive Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…8 At the same time, side effects caused by one drug may be negated by the actions of another drug, resulting in a more favorable tolerability profile. [9][10][11] Amlodipine and candesartan, an angiotensin II type 1 (AT(1)) receptor blocker (ARB), are two widely used drugs in the treatment of hypertension. 12,13 Amlodipine is a calcium channel blocker (CCB).…”

Section: Introductionmentioning

confidence: 99%

Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats

Cheng

Tan

Yu³

et al. 2018

Clin Exp Pharma Physio

View full text Add to dashboard Cite

This study was designed to investigate the possible synergism of amlodipine and candesartan on the reduction of blood pressure (BP) in hypertensive rats. The end organ protection was also observed. In acute experiment, spontaneously hypertensive rats (SHRs) were treated with intragastric administration of amlodipine (0.5, 1, 2, 3 mg/kg), candesartan (1, 2, 3, 4, 6, 8 mg/kg), and 14 different combinations to find the possible ratio of synergistic interaction. In two kidneys, one clip (2K1C) rats, the effects of amlodipine (1 mg/kg), canderastan (2 mg/kg) and their combination on BP reduction were also observed. In chronic study, SHRs were treated with amlodipine (1 mg/kg), candesartan (2 mg/kg), and their combination for 5 months. Organ damage evaluation was performed after BP recording. The probability sum test (q test) was used to evaluate the synergistic action. There is a synergistic interaction between amlodipine and candesartan on BP reduction. The optimal dose ratio is 1:2. The synergistic effect was also confirmed by 2K1C hypertensive rats. In chronic study, this combination (1:2) possessed an obvious synergism on the reduction of BP and BP variability (BPV) and protection on end organs. Multiple regression analysis showed that heart and aortic hypertrophy indexes and glomerular damage parameters were positively related to BP and BPV. In conclusion, combination of amlodipine and candesartan exhibited a potent antihypertensive effect and possessed an obvious synergism on BP reduction and organ protection in hypertension. The optimal proportion was 1:2. BP and BPV reduction may both importantly contribute to end organ protection.

show abstract

“…The goal of antihypertensive therapy is to abolish the risks associated with high blood pressure (BP) without adversely affecting the quality of life [1].…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Determination of Hydrochlorothiazide and Telmisartan from Pharmaceutical Preparations Using Capillary Electrophoresis

Stăcescu¹,

Hancu²,

Gagyi³

et al. 2017

Studia UBB Chemia

View full text Add to dashboard Cite

ABSTRACT. Fixed-dose combinations of an angiotensin II receptor antagonist (telmisartan) and a thiazide diuretic (hydrochlorothiazide) provide an effective antihypertensive therapy while promoting patient compliance with the convenience of once-daily single dose administration. The current study investigated two capillary electrophoretic methods: a capillary zone electrophoresis (CZE) and micellar electrokinetic capillary chromatography one (MEKC) for the simultaneous determination of hydrochlorothiazide and telmisartan. In order to optimize the analytical conditions, efforts were focused on establishing the influence of several experimental parameters on the separation: buffer composition, concentration and pH, applied voltage, temperature, injection pressure and time. The separation of the two analytes can be achieved by CZE using a 25 mM phosphate buffer at pH 2.50 and by MEKC using a 50 mM borate buffer at pH 9.50 containing 25 mM sodium dodecyl sulfate as surfactant. The analytical performance of the two methods was verified in terms of their linearity, precision, accuracy and robustness, and the methods were applied for the determination of the analytes from fixed-dose combinations.

show abstract

Combination therapy for hypertension 2013: An update

Cited by 18 publications

References 46 publications

Effectiveness, Safety and Tolerability of Combination of Amlodipine and Valsartan in Hypertensive Patients

Effectiveness, Safety and Tolerability of Combination of Amlodipine and Valsartan in Hypertensive Patients

Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats

Simultaneous Determination of Hydrochlorothiazide and Telmisartan from Pharmaceutical Preparations Using Capillary Electrophoresis

Contact Info

Product

Resources

About